by Madaline Spencer | Jan 27, 2025
Elias Jabbour, MD, MD Anderson Cancer Center, University of Texas, discusses results of a clinical trial evaluating bleximenib for patients with acute leukemia. Acute myeloid leukemias are a group of neoplasms arising from precursor cells committed to...
by Madaline Spencer | Jan 24, 2025
Martin Dreyling, MD, Ludwig Maximilian University of Munich, discusses results of the TRIANGLE study testing the addition of ibrutinib to treat mantle cell lymphoma. Mantle cell lymphoma is a rare form of malignant non-Hodgkin lymphoma affecting B...
by Madaline Spencer | Jan 23, 2025
Armin Ghobadi, MD, Professor of Medicine and Clinical Director of the Center for Gene and Cellular Immunotherapy at Washington University, discusses results from the ALLELE clinical trial for Epstein-Barr virus positive post-transplant lymphoproliferative disease...
by Madaline Spencer | Jan 22, 2025
David J. Kuter, MD, DPhil, discusses the latest results regarding immune thrombocytopenia (ITP) presented at ASH 2024. ITP is an autoimmune bleeding disorder characterized by too few platelets in the blood. Symptoms may include bruising, nosebleed or...
by Madaline Spencer | Jan 21, 2025
Marina Kremyanskaya, MD, PhD, Icahn School of Medicine at Mount Sinai, discusses the development of gene silencer divesiran for treatment of polycythemia vera (PV). PV is a myeloproliferative disorder characterized by an elevated absolute red blood cell...
